News

UA Associate Vice President Bruce Wright received the COO/Leadership Equivalent Award for a non-profit organization during the 2017 Executive Excellence Award presented by Tucson Local Media and Inside Tucson Business.

Download the FY2017 Annual Report and review our progress against our 2020 vision and our metrics, the achievements of Tech Parks Arizona, and the big picture of the growth of the culture of commercialization throughout the University of Arizona ecosystem.

At a time when opioid addiction represents a major public health crisis, researchers in the UA College of Medicine – Tucson have invented a new class of non-opioid drug candidates to treat pain. The University has licensed the compounds to startup Regulonix.

The UA has licensed a drug that aims to shorten the lives of cancer cells to startup Reglagene. The technology, invented at the UA College of Pharmacy and the BIO5 Institute by Laurence Hurley, PhD, and Vijay Gokhale, PhD, has been shown to be effective in inducing cancer cells to grow old and die.

UA College of Medicine – Tucson Professor Meredith Hay, PhD, and her colleagues started ProNeurogen to commercialize their inventions in neuroscience and cardiovascular neurophysiology. The UA has been awarded two patents for their approach to treating memory loss and cognitive impairment.

UAVenture Capital, LLC has announced the launch of a fund to support the commercialization of University of Arizona science, services and intellectual property. UAVC was formed by Fletcher J. McCusker, the business driver behind the UA College of Pharmacy startup SinfoníaRx.

UA startup SinfoníaRx has been acquired by Tabula Rasa HealthCare (NASDAQ: TRHC), provider of individualized, data-driven technology solutions. Spun out of the College of Pharmacy in 2013, SinfoníaRx pioneered modern medication therapy management (MTM) services.

In October, the Arizona Bioindustry Association, or AZBio, will honor industry leaders from across Arizona. This year, a majority of those to be honored have deep connections to the UA and have created impact through bringing UA ideas and inventions to the marketplace.

The University of Arizona has licensed a new non-skin penetrating sunscreen, invented by UA Professor Douglas Loy and graduate student Stephanie Tolbert, to MexiAloe Laboratorios, S.A. de C.V., a subsidiary of Novamex.

The UA center will use the funding to accelerate development of a Valley fever vaccine for dogs that one day may lead to a successful human vaccine.

Since TLA started in 2012, we have met or exceeded our goals year over year, and are seeing continued growth in the impact originally envisioned for commercialization at the UA. We did it again in FY2017 thanks to your engagement as inventors, experts, advisors and supporters.

The University of Arizona has licensed a pair of technologies to startup Lunewave, Inc. The company is commercializing the College of Engineering inventions to improve automotive radar systems with inexpensive, high-performing 3D printed Luneburg lenses.